Selected article for: "acute respiratory syndrome coronavirus and lung epithelia"
Author: Fatima, Nishat; Kaushik, Vichitra; Ayoub, Amjad
Title: A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19–Recovered Patients as a Probable Therapy for COVID-19
  • Cord-id: c00s6mnr
  • Document date: 2021_5_25
    • ID: c00s6mnr
    Snippet: Coronavirus disease 2019 (COVID-19) emerged as a new contagion during December 2019, since which time it has triggered a rampant spike in fatality rates worldwide due to insufficient medical treatments and a lack of counteragents and prompted the World Health Organization to declare COVID-19 a public health emergency. It is, therefore, vital to accelerate the screening of new molecules or vaccines to win the battle against this pandemic. Experiences from previous epidemiological data on coronavi
    Document: Coronavirus disease 2019 (COVID-19) emerged as a new contagion during December 2019, since which time it has triggered a rampant spike in fatality rates worldwide due to insufficient medical treatments and a lack of counteragents and prompted the World Health Organization to declare COVID-19 a public health emergency. It is, therefore, vital to accelerate the screening of new molecules or vaccines to win the battle against this pandemic. Experiences from previous epidemiological data on coronaviruses guide investigators in designing and exploring new compounds for a safe and cost-effective treatment. Several reports on the severe acute respiratory syndrome (SARS) epidemic indicate that severe acute respiratory syndrome coronavirus (SARS-CoV) and the novel COVID-19 use angiotensin-converting enzyme 2 (ACE2) as a receptor for binding to the host cell in the lung epithelia through the spike protein on their virion surface. ACE2 is a mono-carboxypeptidase best known for cleaving major peptides and substrates. Its degree in human airway epithelia positively correlates with coronavirus infection. The treatment approach can be the neutralization of the virus entering lung epithelial cells by using sera containing antibodies collected from COVID-19–recovered patients. Hence, we herein propose a pulmonary aerosolized formulation or a nasal drop using sera, which contain antibodies to prevent, treat, or immunize against COVID-19 infection

    Search related documents:
    Co phrase search for related documents
    • absorption rate and acute sars cov respiratory syndrome coronavirus: 1, 2
    • action duration and acute respiratory syndrome: 1, 2, 3, 4
    • action duration and acute sars cov respiratory syndrome coronavirus: 1, 2
    • active passive and acute ards respiratory distress syndrome: 1, 2
    • active passive and acute lung injury: 1
    • active passive and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • active passive and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active plasma and acute ards respiratory distress syndrome: 1
    • active plasma and acute lung injury: 1, 2
    • active plasma and acute respiratory syndrome: 1, 2, 3, 4
    • active plasma and acute sars cov respiratory syndrome coronavirus: 1
    • active site and acute ards respiratory distress syndrome: 1, 2
    • active site and acute lung injury: 1, 2
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and add benefit: 1
    • acute respiratory syndrome and add benefit: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and add benefit: 1, 2